MX369451B - Formas cristalinas de compuestos basados en 1, 8- naftiridin-4(h)-ona particulares y su uso en el tratamiento de ansiedad y condiciones relacionadas. - Google Patents
Formas cristalinas de compuestos basados en 1, 8- naftiridin-4(h)-ona particulares y su uso en el tratamiento de ansiedad y condiciones relacionadas.Info
- Publication number
- MX369451B MX369451B MX2015013048A MX2015013048A MX369451B MX 369451 B MX369451 B MX 369451B MX 2015013048 A MX2015013048 A MX 2015013048A MX 2015013048 A MX2015013048 A MX 2015013048A MX 369451 B MX369451 B MX 369451B
- Authority
- MX
- Mexico
- Prior art keywords
- crystalline form
- anxiolytic compound
- compound
- disease
- present
- Prior art date
Links
- 239000002249 anxiolytic agent Substances 0.000 title 1
- 230000000949 anxiolytic effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 229940125904 compound 1 Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361787436P | 2013-03-15 | 2013-03-15 | |
| AU2013204159A AU2013204159B2 (en) | 2013-03-15 | 2013-04-12 | A Crystalline Form of an Anxiolytic Compound |
| PCT/AU2013/000497 WO2014138772A1 (en) | 2013-03-15 | 2013-05-14 | A crystalline form of an anxiolytic compound |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015013048A MX2015013048A (es) | 2016-09-07 |
| MX369451B true MX369451B (es) | 2019-11-08 |
Family
ID=51628585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015013048A MX369451B (es) | 2013-03-15 | 2013-05-14 | Formas cristalinas de compuestos basados en 1, 8- naftiridin-4(h)-ona particulares y su uso en el tratamiento de ansiedad y condiciones relacionadas. |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US9758516B2 (enExample) |
| EP (1) | EP2970290B1 (enExample) |
| JP (2) | JP2016510767A (enExample) |
| CN (2) | CN105377850A (enExample) |
| AU (2) | AU2013204159B2 (enExample) |
| CA (1) | CA2905573C (enExample) |
| MX (1) | MX369451B (enExample) |
| NZ (1) | NZ712341A (enExample) |
| WO (1) | WO2014138772A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105492440A (zh) * | 2013-03-15 | 2016-04-13 | 生态学有限公司 | 抗焦虑化合物的盐、共晶体和多晶型物 |
| WO2018102885A1 (en) * | 2016-12-09 | 2018-06-14 | Bionomics Limited | Modulators of nicotinic acetylcholine receptors and uses thereof |
| WO2019109150A1 (en) * | 2017-12-07 | 2019-06-13 | Bionomics Limited | Methods of treating agitation |
| WO2020087031A1 (en) | 2018-10-26 | 2020-04-30 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| MX2022003347A (es) * | 2019-09-23 | 2022-04-11 | Bionomics Ltd | Formulaciones terapeuticas y usos de las mismas. |
| AU2023201463A1 (en) * | 2023-03-08 | 2024-09-26 | Bionomics Limited | Method of treating social anxiety disorder |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3688827T2 (de) * | 1985-10-25 | 1994-03-31 | Beecham Group Plc | Piperidinderivat, seine Herstellung und seine Verwendung als Arzneimittel. |
| US20060004102A1 (en) * | 2004-05-07 | 2006-01-05 | Shlomit Wizel | Polymorphic forms of nateglinide |
| WO2008046135A1 (en) * | 2006-10-16 | 2008-04-24 | Bionomics Limited | Novel anxiolytic compounds |
| US20140051701A1 (en) * | 2011-03-02 | 2014-02-20 | Bionomics Limited | Methods of treating a disease or condition of the central nervous system |
| AU2012253237B2 (en) * | 2011-05-12 | 2015-09-24 | Bionomics Limited | Methods for preparing naphthyridines |
-
2013
- 2013-04-12 AU AU2013204159A patent/AU2013204159B2/en active Active
- 2013-05-14 MX MX2015013048A patent/MX369451B/es active IP Right Grant
- 2013-05-14 CA CA2905573A patent/CA2905573C/en active Active
- 2013-05-14 AU AU2013382559A patent/AU2013382559A1/en not_active Abandoned
- 2013-05-14 EP EP13878220.6A patent/EP2970290B1/en active Active
- 2013-05-14 NZ NZ712341A patent/NZ712341A/en unknown
- 2013-05-14 JP JP2015561822A patent/JP2016510767A/ja active Pending
- 2013-05-14 WO PCT/AU2013/000497 patent/WO2014138772A1/en not_active Ceased
- 2013-05-14 US US14/776,595 patent/US9758516B2/en active Active
- 2013-05-14 CN CN201380076497.9A patent/CN105377850A/zh active Pending
- 2013-07-12 CN CN201711041313.1A patent/CN107814799A/zh active Pending
-
2017
- 2017-06-29 US US15/638,107 patent/US20170305905A1/en not_active Abandoned
-
2018
- 2018-02-05 JP JP2018018526A patent/JP2018109011A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018109011A (ja) | 2018-07-12 |
| EP2970290A4 (en) | 2016-08-31 |
| CN107814799A (zh) | 2018-03-20 |
| HK1220187A1 (en) | 2017-04-28 |
| US9758516B2 (en) | 2017-09-12 |
| NZ712341A (en) | 2019-07-26 |
| EP2970290A1 (en) | 2016-01-20 |
| US20170305905A1 (en) | 2017-10-26 |
| WO2014138772A1 (en) | 2014-09-18 |
| AU2013204159A1 (en) | 2014-10-02 |
| EP2970290B1 (en) | 2020-07-22 |
| CN105377850A (zh) | 2016-03-02 |
| JP2016510767A (ja) | 2016-04-11 |
| US20160039810A1 (en) | 2016-02-11 |
| MX2015013048A (es) | 2016-09-07 |
| CA2905573A1 (en) | 2014-09-18 |
| AU2013204159B2 (en) | 2015-05-07 |
| CA2905573C (en) | 2021-03-02 |
| AU2013382559A1 (en) | 2015-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019501321A1 (en) | Methods of treating or preventing cholesterol related disorders | |
| SG10201804868PA (en) | Compounds for the inhibition of indoleamine-2,3-dioxygenase | |
| PH12016501966A1 (en) | Compounds and compositions as toll-like receptor 7 agonists | |
| EP3778605A3 (en) | Lrrk2 inhibitors and methods of making and using the same | |
| WO2016044556A3 (en) | Arginine methyltransferase inhibitors and uses thereof | |
| MX2017008518A (es) | Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih). | |
| PH12016500486A1 (en) | Aza-pyridone compounds and uses thereof | |
| NZ724878A (en) | Compounds and compositions as toll-like receptor 7 agonists | |
| MX2015012850A (es) | Inhibidores de la arginina metiltransferasa y usos de los mismos. | |
| MX2015012414A (es) | Sal de omecamtiv mecarbilo y proceso para preparar la sal. | |
| PH12019500196A1 (en) | Compounds and compositions and uses thereof | |
| NZ713809A (en) | 3,4-dihydroisoquinolin-2(1h)-yl compounds | |
| MX2018015082A (es) | Derivado de fenilpropanamida y metodo de fabricacion y su aplicacion farmaceutica. | |
| UA117032C2 (uk) | Селективний інгібітор фосфатидилінозитол-3-кінази-гамма | |
| MX2015010829A (es) | Compuestos terapeuticos y sus usos. | |
| MX2017001103A (es) | Derivados de indolizina que son aplicables a enfermedades neurodegenerativas. | |
| PH12017500451A1 (en) | Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl) oxy)-n, 2-dimethylbenzofuran -3- carboxamide | |
| ZA201803476B (en) | Anti-cd22 antibody-maytansine conjugates and methods of use thereof | |
| PH12020550125A1 (en) | Crystalline forms of 3-substituted 1,2,4-oxadiazole | |
| AU2018253600A1 (en) | Dosage forms and therapeutic uses of l-4-chlorokynurenine | |
| MX369451B (es) | Formas cristalinas de compuestos basados en 1, 8- naftiridin-4(h)-ona particulares y su uso en el tratamiento de ansiedad y condiciones relacionadas. | |
| MX2015013059A (es) | Sales, co-cristales, y polimorfos de un compuesto ansiolitico. | |
| IN2013MU03862A (enExample) | ||
| MX382092B (es) | Compuestos heterocíclicos para el tratamiento de enfermedades. | |
| EA201591717A1 (ru) | Твердые формы гидрохлорида вемурафениба |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |